Apollomics Inc. APLM
Apollomics Inc. (Nasdaq: APLM) is an oncology drug developer. Its lead program, Vebreltinib (APL-101), is in Phase 2 for c-MET altered NSCLC (METex14 skipping, c-MET amplification), brain tumors and other solid tumors with MET alterations. Its next catalyst on record is Vebreltinib: Submit US IND for accelerated approval in 2L NSCLC with c-MET amplification (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Vebreltinib — Submit US IND for accelerated approval in 2L NSCLC with c-MET amplification (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| APL-502 (benmelstobart, anti-PD-L1); China rights out-licensed to CTTQ, approved in China | SCLC, endometrial cancer, RCC (China) | antibody | Phase 3 |
| Vebreltinib (APL-101) - global SPARTA Phase 2 multi-cohort (>282 enrolled) | MET-altered NSCLC and other solid tumors | small molecule | Phase 2 |
| APL-501 (anti-PD-1 IgG4) | Advanced or relapsed/refractory solid tumors | antibody | Phase 1 |
| Vebreltinib + EGFR inhibitor (Phase 2/3 planned) | NSCLC | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.